Effectiveness Of Human Papillomavirus (HPV) Vaccination Against Penile Hpv Infection In Men Who Have Sex With Men And Transgender Women

HPV and Gynecologic Cancer

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

J Low Genit Tract Dis.

Igidbashian S, Boveri S, Bottari F, Vidal Urbinati A, Preti E, Casadio C, Landoni F, Sideri M, Sandri MT.

doi: 10.1097/

HPV and Gynecologic Cancer

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

BMJ Open.

Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, Moscicki AB, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, Franco EL; HPV-007 Study Group

doi: 10.1136/

HPV and Gynecologic Cancer

Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS

Hum Vaccin Immunother.

Orlando G, Frati ER, Fasolo MM, Bianchi S, Matteelli A, Mazza F, Rizzardini G, Amendola A, Tanzi E

doi: 10.1080/21645515.

HPV and Gynecologic Cancer

HPV cervical infections and serological status in vaccinated and unvaccinated women

Vaccine.

Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, Groc S, Rahmoun M, Bender N, Bonneau M, Foulongne V, Graf C, Picot E, Picot MC, Tribout V, Waterboer T, Bravo IG, Reynes J, Segondy M, Boulle N, Alizon S

doi: 10.1016/j.vaccine.2020.10.078.

HPV and Gynecologic Cancer

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Lancet.

Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.

doi: 10.1016/S0140-6736(19)

HPV and Gynecologic Cancer

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

Hum Vaccin Immunother.

Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A

doi: 10.1080/21645515.

HPV and Gynecologic Cancer

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Lancet.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A

doi: 10.1016/

HPV and Gynecologic Cancer

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol

JAMA Netw Open.

Stankiewicz Karita HC, Hauge K, Magaret A, Mao C, Schouten J, Grieco V, Xi LF, Galloway DA, Madeleine MM, Wald A

doi: 10.1001/jamanetworkopen.

HPV and Gynecologic Cancer

Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014

Obstet Gynecol.

Berenson AB, Hirth JM, Chang M

doi: 10.1097/

Related content

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS

HPV cervical infections and serological status in vaccinated and unvaccinated women

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Effect of Human Papillomavirus Vaccine to Interrupt Recurrence of Vulvar and Anal Neoplasia (VIVA): A Trial Protocol

Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014